

Docket No.: 0701.182A

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	<b>Applicant(s):</b> Jerussi <i>et al.</i>	<b>Confirmation No.:</b> 1742
	<b>Serial No.:</b> 10/662.997	<b>Group Art Unit:</b> 1614
	<b>Filed:</b> 09/16/2003	<b>Examiner:</b>
<b>Title:</b> TREATMENT OF CNS DISORDERS WITH <i>trans</i> 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTHALENAMINE		

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This Information Disclosure Statement is

- ☐ submitted together with the application being filed herein; or
- ☐ submitted for the first time; or
- ☒ submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement filed together with the application on September 16, 2003,

and such submission is being made:

- ☒ under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or
- ☐ under 37 CFR 1.97(c) together with either a:
- ☐ Statement under 37 CFR 1.97(e), or
  - ☐ a \$180.00 fee under 37 CFR 1.17(p), after the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or
- ☒ under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a:
- ☐ Statement under 37 CFR 1.97(e), and
  - ☐ a \$180.00 fee set forth in 37 CFR 1.17(p);

**Comment**

- ☐ and, furthermore, please note that:

Applicant(s) submit herewith Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of references.


It is requested that the information disclosed herein be made of record in this application.

**CERTIFICATE OF MAILING**


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Date of Deposit: May 13, 2004

  
EDWARD TIMMER

Respectfully submitted,



EDWARD TIMMER  
Attorney for Applicant(s)  
Registration No. 46,248  
Dated: May 13, 2004

**HESLIN ROTHENBERG FARLEY & MESITI, P.C.**  
5 Columbia Circle  
Albany, New York 12203  
Telephone: (518) 452-5600  
Facsimile: (518) 452-5579



**INFORMATION DISCLOSURE CITATION  
SUPPLEMENTAL**

ATTY DOCKET NO.

0701.182A

SERIAL NO.

10/662,997

APPLICANT(S)

**JERUSSI ET AL**

FILING DATE

09/16/2003

GROUP

1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							NO	YES	ABSTRACT
	BA	EP 0 028 901	28/10/80	EP	C07C 87	457		X	
	BB	EP 0 386 997	06/03/90	EP	A61K 31	135		X	
	BC	WO 99/01121	01/07/97	WO	A61K 31	135		X	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	CG	S.E. Lucangioli, <i>et al.</i> , "Analysis of <i>cis-trans</i> isomers and enantiomers of sertraline by cyclodextrin-modified micellar electrokinetic chromatography", JOURNAL OF CHROMATOGRAPHY A, 871 (2000) 207-215.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial here if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.